TIGIT and neoplasm: A shown in Figure 1, we began treatment of MC38 tumor-bearing mice with anti-TIGIT: mIgG2a and anti-TIGIT:mIgG1* as single agents, or in combination with anti-PD-1 when the tumor size was on average 190 mm3 (Figures 1A,B).